[Immunotherapies and melanoma].

Area of Science:

• Oncology
• Immunology
• Dermatology

Background:

• Metastatic melanoma treatment has evolved significantly in recent years.
• Emergence of targeted therapies and immunotherapies has transformed patient outcomes.

Purpose of the Study:

• To review the impact of novel immunotherapies on metastatic melanoma.
• To compare ipilimumab with newer checkpoint inhibitors (anti-PD-1, anti-PD-L1).
• To discuss future directions in optimizing treatment strategies.

Main Methods:

• Review of recent clinical data and therapeutic strategies.
• Comparison of efficacy and safety profiles of different immunotherapies.
• Analysis of treatment response evaluation criteria.

Main Results:

• Ipilimumab (anti-CTLA4 antibody) improves overall survival in metastatic melanoma.
• Checkpoint inhibitors targeting PD-1 and PD-L1 show promising benefit-risk ratios.
• Adverse events and evaluation criteria differ from traditional therapies.

Conclusions:

• Immunotherapy, particularly checkpoint inhibitors, represents a major advance in metastatic melanoma treatment.
• Optimizing sequential or combination therapies is crucial for maximizing patient benefit.
• Further research is needed to refine these novel treatment paradigms.